Standout Papers
Citation Impact
Citing Papers
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
2012
Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
2012
Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube
2016
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins
2020 StandoutNobel
BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
2013
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
2012
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Targeted therapies for breast cancer
2011
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Triple negative breast cancer: unmet medical needs
2010
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Triple-negative breast cancer: disease entity or title of convenience?
2010
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
2011
Triple-Negative Breast Cancer: An Unmet Medical Need
2011
Mammographic density, breast cancer risk and risk prediction
2007
Cancer type‐dependent genetic interactions between cancer driver alterations indicate plasticity of epistasis across cell types
2015
Triple-Negative Breast Cancer
2010 Standout
Base-excision repair of oxidative DNA damage
2007 StandoutNature
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
2014
A view on drug resistance in cancer
2019 StandoutNature
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy
2015
Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer
2001 Standout
BRCAness revisited
2016
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Cell-cycle checkpoints and cancer
2004 StandoutNature
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
2016
Chk1 and Chk2 kinases in checkpoint control and cancer
2003
Pancreatic cancer
2020 Standout
Ovarian cancer
2014 Standout
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
2013
Alternative splicing and mutation status of CHEK2 in stage III breast cancer
2004
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
2013
Olaparib: First Global Approval
2015
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
2016
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
2012
The Chk2 protein kinase
2004
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010 Standout
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
2016
Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis
2012 StandoutNobel
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
2014
Mucins in ovarian cancer diagnosis and therapy
2009
Medicine and the Nature of Vertical Reasoning
1988
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
2011
Drug development in the era of precision medicine
2017
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Chk2 Oligomerization Studied by Phosphopeptide Ligation
2008 StandoutNobel
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
2010
CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin?
2007
Synthetic lethality: the road to novel therapies for breast cancer
2016
Therapeutic potential of PARP inhibitors for metastatic breast cancer
2011
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
2005 StandoutNature
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
2018
Clonal evolution in cancer
2012 StandoutNature
The PI3K Pathway in Human Disease
2017 Standout
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Comprehensive analysis of the contribution of germline MYH variation to early‐onset colorectal cancer
2004
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Trex1 Exonuclease Degrades ssDNA to Prevent Chronic Checkpoint Activation and Autoimmune Disease
2007 StandoutNobel
PTEN
2014
Practical Approach to Triple-Negative Breast Cancer
2017
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
2011
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
2015
Repeated observation of breast tumor subtypes in independent gene expression data sets
2003 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Ovarian cancer statistics, 2018
2018 Standout
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
2001 Standout
Cellular and Molecular Mechanisms of Drug Dependence
1988 StandoutScience
Metabolic reprogramming and cancer progression
2020 StandoutScience
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
2012
Cancer Genome Landscapes
2013 StandoutScience
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
Olaparib for Metastatic Castration-Resistant Prostate Cancer
2020
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
2020
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
A Randomized Phase II Study of Veliparib with Temozolomide Or Carboplatin/Paclitaxel Versus Placebo with Carboplatin/Paclitaxel in Brca1 / 2 Metastatic Breast Cancer: Design and Rationale
2016
Works of Gillian Mitchell being referenced
Synthetic lethality between CCNE1 amplification and loss of BRCA1
2013
Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations
2013
CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours
2002
False positive 131I whole body scans in thyroid cancer.
2000
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
2015
Analysis of KLLN as a high-penetrance breast cancer predisposition gene
2012
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
2010 Standout
Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches
2002
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
2012
Mammographic Density and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
2006
Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches
2002
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
ANTENATAL DIAGNOSIS OF NEURAL TUBE DEFECTS
1976